Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive
Leerink Partners' David Risinger maintains a Hold rating on AbbVie (ABBV) stock, citing positive Phase 3 tavapadon trial results but cautious about sales projections, remaining trials, and market competition.
Breakthrough for Advanced Myeloma? Talquetamab/Teclistamab Delivers Durable Responses
Talquetamab-tgvs plus teclistamab-cqyv showed a 79.5% overall response rate in triple-class exposed relapsed/refractory multiple myeloma patients, with 52.3% achieving complete response or better. The combination therapy demonstrated a manageable safety profile, with 69.8% progression-free survival at 18 months.
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
J&J's Talvey shows promise in multiple myeloma trials; FDA advisory committee votes against cancer immunotherapy use in certain digestive tract cancers; AbbVie's acquisition of Cerevel Therapeutics yields positive Parkinson's drug results; Roche's Gazyva succeeds in lupus nephritis Phase 3 study; Biogen terminates agreement with Sage Therapeutics over failed essential tremor drug; Enanta Pharmaceuticals' EDP-323 shows rapid antiviral effect against RSV.
Novel combination of TALVEY® (talquetamab) and TECVAYLI®
Updated RedirecTT-1 study results show talquetamab and teclistamab combination yields high response rates and durable responses in relapsed or refractory multiple myeloma patients, with a safety profile consistent to each monotherapy.
Related Clinical Trials:
RIT Co-op Experience Paves Way for Thriving Pharmaceutical Career
Sayali Kadam, a biotechnology student at RIT, leveraged the co-op program to gain industry experience at Johnson & Johnson and Bristol Myers Squibb, discovering her true career path. After graduating, she pursued a Master's at Carnegie Mellon, transitioning into pharmaceutical marketing. Today, she serves as Director of Launch Strategy and Operations at Merck, attributing her success to RIT's scientific foundation, real-world experience, and leadership development.
Tulisokibart bests placebo, may yield 'important clinical benefit' via TL1A blockade in UC
Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.
Global Bispecific Antibody Market Size Bispecific Antibodies
Bispecific antibodies, designed to target two antigens simultaneously, are revolutionizing cancer treatment by enhancing antitumor immune responses and overcoming immune evasion mechanisms. The global market for these antibodies is projected to exceed USD 8 billion by 2023, driven by advancements in antibody engineering and increasing demand for targeted therapies. Major pharmaceutical companies are investing in bispecific antibody research, with strategic collaborations accelerating development. The market is expected to grow further due to expanding therapeutic applications and a shift towards personalized medicine.
Struggling 2Seventy scraps a key cancer study
2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.
Related Clinical Trials:
Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement
Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of ...
Novavax appoints Ruxandra Draghia-Akli, MD, PhD, as EVP and Head of R&D in November 2024, leveraging her 20+ years of clinical, corporate, and global public health expertise to evaluate the company's pipeline and Matrix-M™ adjuvant technology.
© Copyright 2024. All Rights Reserved by MedPath